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Acetylation-induced TDP-43 pathology is
suppressed by an HSF1-dependent chaperone
program
Ping Wang1, Connor M. Wander1, Chao-Xing Yuan2, Michael S. Bereman3 & Todd J. Cohen1
TDP-43 pathology marks a spectrum of multisystem proteinopathies including amyotrophic
lateral sclerosis, frontotemporal lobar degeneration, and sporadic inclusion body myositis.
Surprisingly, it has been challenging to recapitulate this pathology, highlighting an incomplete
understanding of TDP-43 regulatory mechanisms. Here we provide evidence supporting
TDP-43 acetylation as a trigger for disease pathology. Using cultured cells and mouse
skeletal muscle, we show that TDP-43 acetylation-mimics promote TDP-43 phosphorylation
and ubiquitination, perturb mitochondria, and initiate degenerative inflammatory responses
that resemble sporadic inclusion body myositis pathology. Analysis of functionally linked
amyotrophic lateral sclerosis proteins revealed recruitment of p62, ubiquilin-2, and optineurin
to TDP-43 aggregates. We demonstrate that TDP-43 acetylation-mimic pathology is potently
suppressed by an HSF1-dependent mechanism that disaggregates TDP-43. Our study
illustrates bidirectional TDP-43 processing in which TDP-43 aggregation is targeted by a
coordinated chaperone response. Thus, activation or restoration of refolding mechanisms
may alleviate TDP-43 aggregation in tissues that are uniquely susceptible to TDP-43
proteinopathies.
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TDP-43 is the dominant pathology identified in mostamyotrophic lateral sclerosis (ALS) and ~50% of fronto-temporal lobar degeneration (FTLD-TDP) patients. As an
RNA-binding protein, TDP-43 possesses two RNA-recognition
motifs (RRMs), and a C-terminal prion-like domain that harbors
the majority of the familial ALS-associated mutations1–5. While
TDP-43 is predominantly nuclear localized under normal
conditions, pathological TDP-43 found in diseased brain and
spinal cord is abnormally aggregated primarily in the cytoplasm,
which correlates with the onset and progression of TDP-43
proteinopathy by several distinct pathogenic mechanisms6–11.
In addition to the central nervous system (CNS), TDP-43 also
forms pathological inclusions in skeletal muscles of patients with
sporadic inclusion body myositis (sIBM)12–16, suggesting TDP-43
pathology is not solely limited to vulnerable neurons, but likely
induces multisystem proteinopathy in susceptible cell types.
Although it is not fully understood how TDP-43 causes cellular
toxicity, substantial evidence indicates that TDP-43 aggregates
induce loss of normal nuclear TDP-43 functions, as nuclear
depletion of normally soluble TDP-43 and sequestration into
inclusions leads to reduced splicing and RNA stability as well as
activation of cryptic splice sites in cultured cells and transgenic
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Fig. 1 TDP-43 acetylation-mimics promote TDP-43 aggregation in cells. a QBI-293 cells expressing TDP-43-ΔNLS in the absence of ectopic
acetyltransferases were analyzed by mass spectrometry, which identified the K145-acetylated peptide. b A schematic diagram of GFP-tagged TDP-43
constructs used in this study. Basic residues (light brown) within the bipartite nuclear localization sequence (NLS) were mutated to generate cytoplasmic
TDP-43 (TDP-43-ΔNLS). A single glutamine was substituted at position K145 to generate the acetylation-mimic K145Q. c Cells expressing wild-type
TDP-43 and TDP-43-K145Q or cytoplasmic localized TDP-43-ΔNLS and TDP-43-ΔNLS-K145Q were analyzed by double-labeling to detect TDP-43
(green), phospho-TDP-43 using P409/410 (red), and DAPI (blue) to detect nuclei. White arrows highlight highly phosphorylated TDP-43 aggregates.
Scale bar= 50 μm. d Soluble and insoluble fractions isolated from cells expressing the indicated TDP-43 constructs were analyzed by immunoblotting
using TDP-43, P409/410, or GAPDH antibodies. Shown is a representative image from N= 3 independent experiments. The asterisk indicates the
accumulation of ~75–250 kDa TDP-43 species. e Quantification of TDP-43 and phospho-TDP-43 levels illustrate increased insoluble levels of
TDP-43-ΔNLS-K145Q. Error bars indicate SEM and the asterisks indicates statistical significance with ***p-value < 0.001, **p-value < 0.01, and
*p-value < 0.05, as measured by Student’s t-test from N= 3 biological replicates
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mice17–19. As a compensatory response to loss of TDP-43
function, auto-regulation of the TARDBP transcript increases
TDP-43 levels20–22, thereby generating a feed-forward pathogenic
cycle consisting of sustained accumulation of cytosolic TDP-43
that further compromises normal nuclear TDP-43 functions and
potentially alters expression of ~6000 target genes, as shown by
genome-wide TDP-43-binding studies19, 23, 24.
The significance of TDP-43 post-translational modifications as
it relates to TDP-43 aggregation, stability, and clearance
mechanisms is not fully understood. While phosphorylated
TDP-43 at Ser-403/404 and Ser-409/410 is an excellent marker of
disease pathology, several studies indicated that phosphorylation
may prevent rather than promote TDP-43 aggregation25, 26,
suggesting that additional regulation could modulate TDP-43
function. We previously demonstrated that TDP-43 is subject to
reversible lysine acetylation within the RRM domains (residues
K145 and K192), which abrogates the ability of TDP-43 to bind
RNA and also promotes the accumulation of TDP-43 aggregates
in the nucleus and cytoplasm of cultured cells27. We proposed
that acetylation-induced loss of function represents a new
pathogenic mechanism in tissues harboring mostly full-length,
but not truncated, TDP-43 inclusions (e.g., ALS motor
neurons28).
Although acetylated TDP-43 was detected in ALS patient
spinal cord, the pathophysiological relevance of this modification
remained uncertain. However, site-specific TDP-43 acetylation
within the RRM domains combined with the close juxtaposition
of the identified lysine residues (K145 and K192) to the TDP-43/
RNA interface indicates that acetylation may alter charge-
mediated interactions with nucleic acids29, 30. Thus, prolonged
cytoplasmic accumulation could lead to TDP-43 acetylation and
impaired recycling of cytoplasmic TDP-43 back to the nucleus.
Any evidence that acetylation is sufficient to induce TDP-43
pathology in vivo has not been investigated but could provide
valuable insight into the regulation of TDP-43 function and hence
modulation of its downstream targets.
Chaperone-dependent refolding acts in a compensatory
manner to suppress toxic aggregates in a variety of neurodegen-
erative diseases31, 32. In particular, HSF1 is thought to coordinate
stress-activated gene transcription leading to chaperone
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Fig. 2 TDP-43 acetylation-mimics generate hallmark disease pathology in vivo in mouse skeletal muscle. a Immunofluorescence analysis was performed on
mouse tibialis anterior (TA) muscles electroporated with the indicated GFP-tagged TDP-43 plasmids for 4 days. b TA muscle sections were double-labeled
with GFP (green) and dystrophin (Dys, red) antibodies to mark the muscle periphery, while nuclei were stained with DAPI (blue). c TA muscles expressing
TDP-43-ΔNLS-K145Q were double-labeled with GFP and phospho-TDP-43 (P409/410) antibodies to mark pathological TDP-43 aggregates. White arrows
highlight phosphorylated TDP-43 accumulation. d Electroporated TA muscles were harvested, fractionated into soluble and insoluble fractions, and
analyzed by immunoblotting using TDP-43, P409/410, and GAPDH antibodies. Shown is a representative immunoblot from N= 3 independent
experiments. e Quantification of d illustrates increased insoluble TDP-43 in muscles expressing TDP-43-ΔNLS-K145Q. Error bars indicate SEM, and the
asterisk indicates statistical significance with ***p-value < 0.001 and **p-value < 0.01, as measured by Student’s t-test. Scale bar= 50 μm
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induction, aggregate refolding, and re-establishment of cellular
proteostasis33. Loss of HSF1 exacerbates neurodegeneration in
several models34, 35, while overexpression of HSF1 increases
neuronal survival36, 37. Global genome-wide studies indicate
that both small and large heat shock proteins (HSPs) as well as
non-HSP targets may be critical for HSF1-dependent neuropro-
tection38, 39. However, HSF1 activation may not be readily
achieved in neurons due to a higher threshold requirement for
sustained HSF1 activity40, 41. Nonetheless, the HSF-1 targets
Hsp40 and Hsp70 were recruited to full-length TDP-43 foci and
phosphorylated C-terminal fragments42 and also were sufficient
to partially suppress TDP-43 aggregation43, 44. Whether increased
chaperone activity is a viable strategy to alleviate aggregate
burden in TDP-43 proteinopathies is not clear.
Here, we show that expression of acetylation-mimic TDP-43
mutants at residue K145 induces robust TDP-43 pathology
characterized by insoluble, hyper-phosphorylated, and ubiquiti-
nated TDP-43 aggregates that are readily engaged by components
of the autophagy and ubiquitin-proteasome degradation
machinery. To alleviate acetylation mimic-induced aggregation,
HSF1 was activated by genetic or pharmacological approaches,
which led to induction of a transcriptional chaperone program
capable of clearing cytoplasmic TDP-43 aggregates. Our study
provides bidirectional formation and clearance of TDP-43
pathology, the latter of which occurs via an endogenous refold-
ing program, suggesting that latent chaperone activity holds
promise for the amelioration of TDP-43 pathology in the CNS
and other susceptible tissue types.
Results
TDP-43 acetylation-mimic at K145 induces TDP-43 aggrega-
tion. Our previous study identified acetylated residue K145 in
RRM1 as a major site of TDP-43 acetylation induced by the
acetyltransferase CREB-binding protein (CBP)27. Mass spectro-
metry analysis in the absence of ectopic CBP also detected
K145 acetylation (Fig. 1a), suggesting steady-state TDP-43 acet-
ylation occurs under normal cellular conditions. We therefore
generated a series of GFP-tagged constructs expressing nuclear or
cytoplasmic localized (ΔNLS) TDP-43 lacking or containing
acetylation-mimic K-to-Q substitutions at position K145
(Fig. 1b). Compared to wild-type TDP-43 (TDP-43-WT),
expression of nuclear acetylation-mimic TDP-43-K145Q formed
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Fig. 3 TDP-43 acetylation-mimic aggregates recruit the degradative machinery and promote mitochondrial dysfunction. a Cells expressing aggregate-prone
TDP-43-ΔNLS-K145Q were analyzed by double-labeling using ubiquitin, 20S proteasome, or p62 antibodies, and counterstained with DAPI (blue).
White arrows highlight co-localization of ubiquitin, 20S proteasome, or p62 with TDP-43 aggregates. b Mouse TA muscles electroporated with TDP-43-
ΔNLS-K145Q for 14 days were similarly analyzed using ubiquitin, 20S proteasome, and p62 antibodies. White arrows highlight prominent co-localization of
TDP-43 aggregates with ubiquitin, 20S proteasome, or p62 in mouse muscles. c, d Mouse tissues were analyzed by immunoblotting (c) or microscopy
(d) using ubiquitin or p62 antibodies, as well as the mitochondrial panel of antibody markers (COXIV, TOM20 and Cytochrome c). Scale bar= 50 μm
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distinct stippled nuclear foci that were partially phosphorylated
at known pathological epitopes (S409/410) (Fig. 1c, compare
TDP-43-WT to TDP-43-K145Q). The cytoplasmic acetylation-
mimic TDP-43-ΔNLS-K145Q produced inclusions that were
more robustly phospho-TDP-43 immunoreactive (Fig. 1c, see
TDP-43-ΔNLS-K145Q), resembling full-length cytoplasmic
TDP-43 pathology in ALS spinal cord. In agreement with the
immunofluorescence results, immunoblotting detected abundant
insoluble and hyper-phosphorylated TDP-43-ΔNLS-K145Q
aggregates (Fig. 1d, e, Supplementary Fig. 1). The accumulation of
~75–250 kDa TDP-43 species (Fig. 1d, see asterisk) is consistent
with multimeric TDP-43 species observed in response to oxida-
tive stressors45. In contrast to K-to-Q mutations, either K-to-R
non-mimic mutations or known ALS-associated mutations,
whether targeted to either the nucleus or the cytoplasm of
cultured cells, has not produced comparable levels of TDP-43
aggregates45. Enhanced TDP-43 aggregation due to the K145Q
acetylation-mimic was observed in all cell lines tested including
motor neuron-like NSC-34 cells (Supplementary Fig. 2).
We hypothesized that TDP-43 aggregation would be conserved
in both skeletal muscle and CNS tissues, both of which are
vulnerable to TDP-43 pathology. We employed an in vivo
electroporation system to efficiently deliver TDP-43 to mouse
tibialis anterior (TA) muscles (Fig. 2a)46. Confocal imaging
of electroporated muscle fibers showed nuclear localization of
TDP-43-WT, while TDP-43-K145Q accumulated as punctate
aggregates throughout the myofiber in both the nucleus and
sarcoplasm. The TDP-43-K145Q localization pattern could
indicate that myofibers generate a more cytoplasmic and
aggregate-prone phenotype compared to that previously observed
in cell lines27. Even more pronounced punctate aggregation was
observed with the cytoplasmic localized TDP-43-ΔNLS-K145Q
mutant (Fig. 2b, Supplementary Fig. 3, see aggregates within
myofibers highlighted by asterisk). The ectopically produced
mutant TDP-43 pathology generated in myofibers was robustly
phosphorylated at S409/410 and showed abnormal localization to
perinuclear regions, the muscle membrane, and also centrally
within muscle fibers (Fig. 2c, white arrows, Supplementary Fig. 3).
While TDP-43-WT displayed normal nuclear TDP-43 staining
patterns, TDP-43-ΔNLS lacking acetylation-mimic mutations
appeared to accumulate immediately surrounding and possibly
adhered to the nuclear membrane (Fig. 2b, Supplementary Fig. 3).
This unique TDP-43-ΔNLS staining pattern could similarly
reflect increased aggregation propensity in myofibers compared
to cultured cells, leading to more rapid cytoplasmic deposition
adjacent to the nuclear membrane. Subsequent immunoblotting
of muscle homogenates confirmed the accumulation of phos-
phorylated TDP-43 aggregates generated by TDP-43-K145Q and
more prominently by TDP-43-ΔNLS-K145Q (Fig. 2d, e,
Supplementary Fig. 4). Thus, in vivo expression of TDP-43
acetylation-mimics is sufficient to rapidly (within days) generate
TDP-43 pathology that resembles human sIBM skeletal muscle.
TDP-43 acetylation-mimic alters cellular proteostasis. To
further characterize acetylation-mimic induced TDP-43 pathol-
ogy, we analyzed known proteasome and autophagy markers
implicated in TDP-43 protein clearance pathways1. In cells
(Fig. 3a) or myofibers (Fig. 3b), a subset of cytoplasmic aggregates
were ubiquitinated, as assessed by anti-ubiquitin antibodies, while
the 20S proteasome was also recruited but was less prominently
localized to TDP-43 aggregates (Fig. 3a, b, white arrows). Simi-
larly, the autophagy marker p62 strongly localized to TDP-43
aggregates (Fig. 3a, b, white arrows). Consistent with impaired
degradative function, however, we observed accumulation of
high-molecular weight ubiquitin-positive smearing in insoluble
muscle fractions (Fig. 3c, Supplementary Fig. 5). Indeed, mass
spectrometry analysis of immunopurified TDP-43-ΔNLS-K145Q
protein identified a specific ubiquitinated residue, K181, within
the TDP-43 RRM linker region (Supplementary Fig. 6), further
suggesting proteasome targeting of the aggregate-prone TDP-43
acetylation-mimic.
Mitochondria are perturbed in ALS patients and mouse models
of ALS47–52. We therefore asked whether TDP-43 expressing
muscle fibers displayed mitochondrial abnormalities in biochem-
ical fractions of muscle extracts. While TDP-43-WT did not alter
the levels of any mitochondrial markers tested, TDP-43-K145Q
or cytoplasmic targeted TDP-43 (independent of its acetylation-
mimic status) appeared to increase mitochondrial aggregation, as
detected by high-molecular-weight species using three indepen-
dent mitochondrial markers (TOM20, COXIV, and Cytochrome
c) (Fig. 3c, Supplementary Fig. 5, see insoluble mitochondrial
smearing53). There were negligible effects on soluble mitochon-
dria contents. Furthermore, accumulation of Cytochrome c and
COXIV immunoreactivity co-localized with TDP-43 aggregates
in electroporated myofibers (Fig. 3d). Mitochondrial aggregates
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Fig. 4 Functionally linked co-pathologies emerge in response to TDP-43 acetylation-mimic aggregates. QBI-293 cells (a) or TA muscles (b) were
transfected with GFP-tagged cytoplasmic localized TDP-43-ΔNLS-K145Q either alone (endogenous UBQLN-2 analysis) or in tandem with an OPTN
expression plasmid for increased detection sensitivity. Either endogenous UBQLN-2 or ectopically expressed OPTN were detected by double-labeling
immunofluorescence using GFP (green), UBQLN-2 (red), or OPTN (red) antibodies, while DAPI marked nuclei (blue). We note significant recruitment of
both UBQLN-2 and OPTN to TDP-43 aggregates in either cell-based or muscle fiber models. White arrows highlight recruitment of UBQLN-2 or OPTN to
TDP-43 aggregates. Arrowheads indicate occasional co-localization of UBQLN-2 to smaller TDP-43 pre-aggregates. Scale bar= 50 μm
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have been observed in several TDP-43 mouse models49, 51,
suggesting that abnormal TDP-43 conformation, whether weakly
or strongly aggregated, may be sufficient to induce mitochondrial
damage and activation of clearance mechanisms.
TDP-43 inclusions in sIBM, ALS, and FTLD-TDP tissues
partly co-localize with other functionally linked ALS proteins that
mediate proteasome or autophagic degradation54, 55. Cells
(Fig. 4a) or myofibers (Fig. 4b) expressing aggregate-prone
TDP-43-ΔNLS-K145Q were double-labeled and analyzed for
recruitment of ubiquilin-2 (UBQLN-2) or optineurin (OPTN).
Consistent with recruitment of degradative factors, cytoplasmic
TDP-43 aggregates co-localized prominently with UBQLN-2 and
OPTN (Fig. 4a, b, white arrows). We note that UBQLN-2
occasionally localized to smaller more discrete TDP-43 foci
(Fig. 4a, see white arrowheads), potentially reflecting a
pre-aggregated pool of TDP-43 targeted by UBQLN-2. The
acetylation-mimic TDP-43 aggregates therefore generate over-
lapping co-pathologies that converge on several functionally
related proteins implicated in ALS pathogenesis.
Since acetylation-mimic TDP-43 aggregates co-localized with
p62, a sensitive and specific marker of sIBM56, we further
assessed whether ectopically generated muscle aggregates
produced a sIBM myofiber phenotype. Normal endogenous
TDP-43 is almost exclusively nuclear localized by immunohis-
tochemistry (IHC) analysis, as expected (Fig. 5a). Prolonged
expression of TDP-43-ΔNLS-K145Q for 22 days in vivo led to a
striking accumulation of large TDP-43 inclusions within the
myofiber sarcoplasm (Fig. 5a, black asterisk, and Fig. 5b, white
arrow), suggesting an inability to clear mature TDP-43
aggregates. We observed accumulation of interstitial cells
surrounding TDP-43-ΔNLS-K145Q electroporated myofibers,
but not in TDP-43-WT expressing fibers (Fig. 5b). Double-
labeling experiments suggested that infiltrating CD8+ T-cells
were present surrounding aggregate-bearing myofibers (Fig. 5c),
an inflammatory response that is implicated in myofiber damage
in sIBM12. Finally, TDP-43-positive necrotic myofibers also
contained classic rimmed vacuoles that were observed by H&E
and Gomori trichrome stains (Fig. 5d), indicating lysosomal
dysfunction induced by the sustained accumulation of TDP-43
pathology.
To determine whether the aggregate burden compromised
myofiber integrity, Evans blue dye (EBD) was intraperitoneal
(i.p.) injected into mice prior to muscle tissue harvest. Upon
membrane damage EBD is taken up into myofibers and readily
detected by immunofluorescence. However, no EBD uptake was
observed in TDP-43 transfected myofibers, and we observed very
rare EBD-positive fibers in the entire muscle tissue irrespective of
ectopic TDP-43 expression, consistent with a lack of overt muscle
membrane damage induced by TDP-43 pathology (Supplemen-
tary Fig. 7, see white arrows). We conclude that acetylation-mimic
TDP-43 recapitulates several key hallmarks of sIBM when
introduced into muscle including TDP-43 aggregation, myofiber
degeneration, and T-cell-mediated inflammatory responses.
HSF1 suppresses acetylation-mimic TDP-43 pathology. We
next sought to identify clearance mechanisms as cytoprotective
avenues to reduce acetylation-mimic TDP-43 pathology. HSF1, a
master regulator of the cellular chaperone response, could facil-
itate the disaggregation of TDP-43 aggregates by virtue of its
transcriptional induction of chaperone-dependent refolding.
We took advantage of a previously engineered HSF1 mutant
containing a single amino-acid substitution (L395E) and
also lacking an auto-inhibitory domain (Δ221–315) that showed
~10-fold increased DNA-binding activity36 (see Fig. 6a sche-
matic). Wild-type HSF1, constitutively active HSF1 (Δ221–315,
L395E), or an inactive DNA-binding-deficient HSF1 mutant
(R71G) were individually co-expressed with TDP-43-ΔNLS-
K145Q. Strikingly, wild-type HSF1 and more prominently active
HSF1, but not the inactive HSF1, reduced insoluble phosphory-
lated TDP-43-ΔNLS-K145Q inclusions with no apparent effect
on the soluble TDP-43 pool (Fig. 6b, c, Supplementary Fig. 8).
These results were confirmed by immunofluorescence, which
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Fig. 5 Chronic TDP-43 pathology that persists in skeletal muscles recapitulates aspects of sIBM pathology. Mouse TA muscles were mock
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showed ~90% reduction of phosphorylated TDP-43 inclusions in
the presence of active HSF1 (Fig. 6d, e).
We next assessed whether delayed expression of HSF1 was
sufficient to disaggregate pre-formed acetylation-mimic TDP-43
aggregates. Indeed, only introduction of the active HSF1 reduced
the pre-formed insoluble TDP-43 pool (Fig. 6f, g, Supplementary
Fig. 8). Blocking either proteasome or autophagy-mediated
degradation prevented HSF1-mediated disaggregation and
restored insoluble TDP-43-ΔNLS-K145Q levels with no apparent
effect on the soluble TDP-43 pool (Supplementary Fig. 9).
Therefore, refolded insoluble TDP-43-ΔNLS-K145Q aggregates
may be targeted for degradation via both pathways, with what
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appears to be a more dominant role for the proteasome. To
confirm these observations using a pharmacological approach,
cells expressing acetylated TDP-43 aggregates were exposed to
HSF1A, a compound that inhibits the TRiC protein complex
thereby facilitating nuclear HSF1 accumulation, trimerization,
and enhanced DNA binding57. HSF1A treatment for 24 h
significantly reduced TDP-43 inclusion formation (Fig. 6h, i),
suggesting that activation of endogenous HSF1 is sufficient to
disaggregate TDP-43. Interestingly, suppression of TDP-43
aggregation was not observed in response to other reported
HSF1 modulating compounds including the Hsp90 inhibitor
17-AAG and the current FDA-approved ALS drug riluzole
(Supplementary Fig. 10)58.
To assess whether HSF1 mediates TDP-43 aggregate clearance
in vivo, we co-electroporated TDP-43-ΔNLS-K145Q with the
indicated HSF1 constructs, or as a loss of function an HSF1-
specific siRNA (Supplementary Fig. 11), into muscle fibers and
TDP-43 aggregation was assessed by immunofluorescence.
Similar to the cell-based approach, we observed significantly
reduced overall TDP-43 aggregate burden in myofibers expres-
sing active HSF1, and only small punctate TDP-43 foci remained
(Fig. 7a, b). Importantly, these effects were not observed with the
inactive HSF1 mutant. We further confirmed these observations
using adjacently stained myofibers, in which HSF1 suppressed
TDP-43 aggregation, but not in an adjacent myofiber that lacked
HSF1 (Fig. 7c). Quantification of these results indicated that
active HSF1 reduced TDP-43 aggregation in vivo by ~5-fold
(Fig. 7d). While siRNA-mediated depletion of endogenous HSF1
in myofibers showed a trend toward increased TDP-43 aggrega-
tion, this was not statistically significant under the parameters
and conditions tested (Fig. 7d).
HSPs engage and suppress TDP-43 acetylation-mimic aggre-
gates. To investigate the targets of HSF1 that mediate TDP-43
disaggregation, we examined expression of a panel of HSPs
that are transcriptionally induced by HSF1. We observed
minimal induction of some HSPs (Hsp70, Hsp90, Hsp110),
however, active HSF1 led to a more pronounced ~1.7–2.0 fold
induction of Hsp27 and Hsp40 (Fig. 8a, b, Supplementary
Fig. 12), two critical chaperones that are genetically linked to
limb-girdle muscular dystrophy and primary motor neuropathy,
respectively59, 60. While endogenous Hsp40, but not Hsp27, was
physically recruited to cytoplasmic TDP-43 aggregates (Fig. 8c,
see aggregates denoted by arrows), overexpression of either
Hsp27 or Hsp40 was sufficient to suppress TDP-43 aggregation
by immunofluorescence (Fig. 8d) and immunoblotting (Fig. 8e,
Supplementary Fig. 12), which cleared the majority of TDP-43
aggregates, as only ~5–10% GFP-positive TDP-43 inclusions
remained (Fig. 8f, g).
To assess whether Hsp27 or Hsp40 are necessary for HSF1-
mediated suppression of TDP-43 aggregation, we examined
whether siRNA-mediated knockdown of either chaperone could
effectively prevent HSF1 from clearing TDP-43 aggregates
(Fig. 9a, Supplementary Figs. 13 and 14). Hsp27 siRNA slightly
restored insoluble TDP-43 levels (Fig. 9a, compare lane 1 to lanes
6–7), while Hsp40 siRNA alone, and to a greater extent the
combined Hsp27/Hsp40 double siRNA, nearly completely
restored TDP-43 aggregation and eliminated much of the
disaggregation effects mediated by HSF1 (Fig. 9a, compare lane
1 to lanes 4–5 and 8–9). Quantification of these results suggests a
synergistic involvement of both Hsp27 and Hsp40, with a more
dominant role for Hsp40 in the clearance of TDP-43 aggregates
(Fig. 9b).
Given the striking suppression of TDP-43 aggregation by
Hsp40, we examined whether Hsp40 is linked to TDP-43
pathology in vivo by immunohistochemistry analysis of human
ALS spinal cord. Hsp40 localization was diffusely cytoplasmic in
the majority of ALS motor neurons with occasional focal, round,
cytoplasmic immunoreactivity (Fig. 9c, black arrows). The Hsp40
immunoreactive structures were, in part, TDP-43-positive ALS
lesions, as double-labeling revealed co-localization of Hsp40 with
phosphorylated TDP-43 inclusions (Fig. 9c, see white arrow in
merged image). Interestingly, in contrast to round TDP-43
inclusions, skein-like amorphous TDP-43 inclusions did not
contain Hsp40 in the subset of ALS cases analyzed (Fig. 9c, see
white arrowhead), suggesting that Hsp40 recruitment to TDP-43
aggregates may alter inclusion morphology and/or processing of
its contents for degradation. Overall, our results support the
notion that Hsp40 initially acts in a cytoprotective capacity to
suppress toxic TDP-43 aggregation, but may be insufficient to
counteract the full burden of TDP-43 pathology that accumulates
in end-stage ALS spinal cord.
Discussion
In this study, we provide strong evidence for acetylation-mimic
induced full-length TDP-43 pathology in vitro and in vivo. A
single acetylation-mimic (K145Q) that modulates TDP-43 RNA
regulatory functions led to robust aggregation that was sufficient,
when targeted to the cytoplasm, to trigger many of the patholo-
gical hallmarks associated with TDP-43 proteinopathy including
hyper-phosphorylation, recruitment of functionally linked ALS
proteins, perturbations of mitochondria, and an associated
inflammatory signature. We provide evidence that enhanced
chaperone function alleviated the burden of TDP-43 aggregates
via an HSF-1 transcriptional cascade, suggesting an endogenous
refolding program is capable of engaging and clearing TDP-43
inclusions in vivo. Our study suggests that pharmacological
approaches to specifically target and enhance chaperone-
dependent aggregate processing may restore proteostasis in
individuals with ALS, sIBM, and other TDP-43 proteinopathies.
Our prior study suggested that acetylation achieved with the
acetyltransferase CBP or K-to-Q mimics, but not K-to-R non-
Fig. 6 An HSF1-dependent transcriptional program suppresses TDP-43 acetylation-mimic-induced aggregation. a Schematic diagram of HSF1 constructs
highlighting active and inactive mutations. The regulatory domain (RD) was deleted and a single L395E was introduced to generate active HSF1, while R71G
represents inactive HSF1. DBD DNA-binding domain, HR hydrophobic heptad repeat domain. b Cells were transfected with TDP-43-ΔNLS-K145Q in
combination with the various HSF1 constructs (or control pCDNA vector) followed by biochemical fractionation and immunoblotting using the indicated
TDP-43, P409/410, HSF1-HA, or GAPDH antibodies. Shown is a representative image containing duplicate samples from N= 3 independent experiments.
c TDP-43 and phospho-TDP-43 levels from b were quantified by densitometry. d Cells expressing constructs similar to c above were analyzed by
immunofluorescence using GFP and P409/410 antibodies. White arrows highlight phosphorylated TDP-43 aggregates. e Inclusion formation in d was
quantified. f A sequential transfection was performed first with TDP-43-ΔNLS-K145Q followed by subsequent transfection of HSF1 for another 48 h.
Soluble and insoluble fractions were analyzed by immunoblotting using the indicated antibodies. g Insoluble TDP-43 and phospho-TDP-43 were quantified,
showing reduction of pre-formed TDP-43 aggregates by active HSF1. h Cells expressing TDP-43-ΔNLS-K145Q aggregates were exposed to DMSO or
HSF1A and analyzed by immunofluorescence. i Aggregates were quantified and normalized to the number of total TDP-43 expressing cells. Error bars
indicate SEM, and the asterisk indicates statistical significance with ***p-value < 0.001 and **p-value < 0.01, as measured by Student’s t-test from N= 3
biological replicates. ns= not significant. Scale bar= 50 μm
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mimics, could abrogate TDP-43-RNA interactions leading to
unstable TDP-43 conformation and aggregation27. However the
significance of this observation in vivo remained unclear. Using
electroporated skeletal muscle, acetylation-mimic TDP-43
generated a strong aggregate-prone phenotype, especially when
targeted to the cytoplasm. This observation is consistent with
more abundant TDP-43 pathology occurring in the cytoplasmic
compartment. Recent studies in vitro have shown that loss of
nucleic acid binding converts TDP-43 into unstable insoluble
aggregates61, 62, implying that physical association with nucleic
acids may act to stabilize the TDP-43 C-terminal prion-like
domain, leading to more soluble functional protein. Acetylation
may therefore act as a regulatory switch to modulate TDP-43
affinity for target RNAs. Indeed, treatment of cells with agents
that increase oxidative stress and promote loss of RNA binding
led to acetylated and insoluble accumulation of TDP-4327. Resi-
due K145 maps to an exposed lysine residue in close proximity to
the DNA/RNA-binding interface30, likely a more accessible
region allowing rapid regulation of TDP-43 activity. Whether
acetylation at other TDP-43 lysines also regulates TDP-43
aggregation is not currently known, but mass spectrometry ana-
lysis in vitro also detected K192 acetylation in RRM227.
Therefore, specific acetylation events within each RRM may
converge to coordinately regulate TDP-43-binding affinity and
hence its RNA regulatory functions.
While TDP-43 pathology correlates with degeneration in vivo,
it is not entirely clear whether TDP-43 inclusions directly cause
neurotoxicity. However, cytosolic TDP-43 accumulation likely
drives an auto-regulatory cascade leading to further TDP-43
recruitment into cytosolic aggregates and loss of normal nuclear
functions. TDP-43 inclusions therefore likely cause both loss and
gain of function toxicity, however in vivo models of enhanced
TDP-43 aggregation have been challenging to recapitulate.
Recently, more robust full-length TDP-43 pathology in brain and
spinal cord was achieved with NEFH promoter-driven expression
of cytoplasmic TDP-43-ΔNLS leading to neurodegeneration and
muscle denervation63, indicating that higher level spinal cord
expression may be required for more robust pathology. However,
the authors noted that large inclusions typically seen in ALS
patients were present in only a minority of motor neurons. Our
ability to generate rapid, robust, and widespread TDP-43
pathology likely reflects a critical loss of nucleic acid binding
associated with the K145Q acetylation-mimic mutation. The near
absence of disease-causing mutations within the RRM domains
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(or surrounding the K145 residue) could reflect lethality
associated with sustained RNA-binding deficiency, which
conceivably would impact the splicing and/or expression of up to
~6000 TDP-43 targets in neurons, many of which are essential for
synaptic function19. In this regard, there is debate about whether
TDP-43 binding to downstream targets promotes or alleviates
toxicity, as several studies indicate that loss of RNA binding can
suppress TDP-43-mediated toxicity64, 65. In contrast, our results
support the notion that acetylation induces loss of RNA binding,
enhanced aggregation, and progressive degeneration (Fig. 5).
However, we cannot currently exclude the possibility that
acetylated TDP-43, at least in part, acquires new RNA-binding
properties, as previously proposed for some ALS-associated
TDP-43 mutations66.
HSF1 has been implicated in aggregate clearance and neuro-
protection, particularly in SOD1-dependent ALS models leading
to delayed disease onset and progression37, 67. In addition, HSF1
activating compounds including arimoclomol reduced SOD1
aggregation and were neuroprotective68. Our results suggest that
TDP-43 is also targeted by an endogenous refolding program,
which is consistent with two recent studies43, 44. However, HSF1
may be kept partially inactive in tissues that are uniquely vul-
nerable to TDP-43 pathology including skeletal muscle and CNS
tissues. Supporting this possibility, neurons were shown to pos-
sess an unusually high threshold for HSF1 activation and
subsequent HSP induction40. Thus, enhanced pharmacological
HSF1 activation may have therapeutic value in ameliorating
TDP-43 pathology. Since sustained HSF1 activity is associated
with tumor metastasis and progression69, an alternative approach
could target critical downstream chaperones including small
HSPs (Hsp27) and Hsp40 that are most highly induced by HSF1
and capable of suppressing TDP-43 aggregates (Fig. 8)43, 44.
While the roles of these HSPs in TDP-43 proteinopathies are not
fully understood, genetic mutations in DNAJB1 and HSPB1 that
encode Hsp40 and Hsp27 are associated with limb-girdle
muscular dystrophy and motor neuropathies59, 60. Furthermore,
Hsp27 expression alone is sufficient to delay motor phenotypes
and increase motor neuron survival in SOD1-G93A mice70. Thus,
proper Hsp27/40 expression in combination with proper
subcellular localization and target engagement (i.e., TDP-43
aggregates) may be critical to achieve optimal aggregate sup-
pression. Future efforts to modulate HSPs in the recently
described TDP-43 transgenic mice63 may provide insight into
HSP function in the context of more robust brain and spinal cord
pathology.
While HSF-1 led to disaggregation of pre-formed TDP-43
aggregates, residual TDP-43 aggregates still remained (Fig. 6f, g),
indicating that synergistic approaches to boost chaperone activity
may be advantageous. For example, recent efforts to engineer
variants of the AAA+ ATPase Hsp104 have proven extremely
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effective against a wide range of protein aggregates including tau,
α-synuclein, and TDP-4371. While our data suggest that HSPs
mediate most of the protective effects of HSF1, non-HSPs
downstream of HSF-1 may also be relevant in mediating TDP-43
disaggregation38. In this regard, transcriptomic approaches may
be necessary to clarify the range of specific HSF1 targets that are
inducible in brain, spinal cord, or skeletal muscle in vivo. We
speculate that vulnerability to TDP-43 aggregate formation may
be explained by a lack of sufficient HSF1 levels and/or function
in vivo. Therefore, efforts to augment or restore HSF1 activity or
downstream chaperone function could provide therapeutic
opportunities to combat a range of multisystem TDP-43 protei-
nopathies affecting both CNS and non-CNS tissues alike.
Methods
Plasmids and cell culture. QBI-293 cells (MP Biomedicals) and Neuro2A cells
(ATCC) are commercially available. NSC-34 cells were originally purchased from
Tebu-Bio and kindly provided by Dr. Nikolay Dokholyan (University of North
Carolina). All mammalian expression plasmids were amplified in DH5α bacteria
(New England Biolabs). TDP-43 constructs were generated using either pEGFP-C1
or DsRed-C1 vectors (Clontech) and K-to-Q mutations at residue K145 were
created by site-directed mutagenesis (Quikchange kit; Stratagene) using primers
listed in Supplementary Table 1. Human HSF1 (hHSF1) constructs were kindly
provided by Dr. Dennis Thiele (Duke University) and mutated to active and
inactive forms using the same strategy. The regulatory domain (RD) was deleted
and a single L-to-E mutation at residue L395 was introduced to generate the active
form of HSF1, while R71G was generated for inactive HSF1. Human optineurin
(OPTN) and ubiquilin-2 (UBQLN-2) expression plasmids were purchased from
Addgene. Plasmids were transfected into QBI-293 or NSC-34 cells using Fugene 6
(Promega) or Lipofectamine 2000 (Thermo Fisher Scientific) following the
manufacturer’s instructions. For HSP siRNA treatment, cells were cultured in
six-well plates for 24 h prior to transfection. Co-transfection of multiple plasmids
(e.g., TDP-43-ΔNLS-K145Q combined with control PCDNA or HSF1-active) or
siRNA duplexes (targeting Hsp40 or Hsp27, Santa Cruz Biotechnology) was
performed using Lipofectamine 2000 per the manufacturer’s protocols. All siRNAs
were transfected twice sequentially to achieve optimal siRNA knockdown (50 pmol
incubated for 24 h performed twice).
For HSF1 siRNA treatment (Supplementary Table 1), Neuro2A cells were
treated with control or a panel of HSF1 siRNA for 72 h. Cells were harvested and
analyzed by immunoblotting using an HSF1 antibody (Enzo Life Sciences). For
sequential transfection, QBI-293 cells were first transfected using Fugene 6 with
TDP-43-ΔNLS-K145Q for 18 h, and then transfected again with control vector,
wild-type HSF1, HSF1 active, or HSF1 R71G mutant plasmids for another 48 h.
Cells were harvested and analyzed by immunoblotting using the indicated
antibodies as described in text. For HSF1A (Axon Medchem) drug treatment,
QBI-293 cells were grown on poly-D-lysine-coated coverslips and transfected as
described above, treated with 10 µM HSF1A or DMSO for 24 h and analyzed by
confocal microscopy. For riluzole and 17-AAG treatments, cells were treated with
riluzole (5 μM) or 17-AAG (5 μM) (Sigma) for 24 h and analyzed by
immunoblotting. For MG-132 or 3-methyladenine (3-MA) drug treatments,
QBI-293 cells were cultured in six-well plates for 24 h prior to transfection.
TDP-43-ΔNLS-K145Q was transfected first, then active HSF1 was added ~12 h
after the initial transfection. After 48 h, cells were treated with MG-132 (1 μM) or
3-MA (10 mM) for 24 h. Cells were harvested and analyzed by immunoblotting
using the indicated antibodies, as described in the text. For NSC-34 cell culture
experiments, cells were maintained in high-glucose DMEM formulation (D5796,
Sigma) supplemented with 10% FBS. NSC-34 transfections were performed on
poly-D-lysine-coated coverslips, and plasmids were transfected for 48 h using
Lipofectamine 2000 (Life Technologies) following the manufacturer’s protocols,
followed by confocal microscopy, as described below.
Skeletal muscle electroporation. All experiments were performed in strict
compliance with animal protocols approved by the Institutional Animal Care and
Use Committees (IACUC) of the University of North Carolina at Chapel Hill
(under approved protocol 14.107.0). C57BL6 mice were obtained from Charles
River Laboratories and used for this study. Mouse muscle electroporations were
performed based on a high-efficiency protocol that was developed in skeletal
muscle46. The detailed procedure is as follows: Wild-type 12-week-old C57BL/6
mice (male and female) were treated with hyaluronidase, 5 mg ml−1 in 0.9% saline
1 h before injection. TA muscles were then injected with 50 μl hyaluronidase per
leg and treated for 45 min. The mice were anesthetized using Avertin (1.25% in
phosphate-buffered saline (PBS), Sigma) and fur was removed with Nair. Using 25
μl microsyringe (VWR), plasmids (25 μl of 0.2–0.4 μg μl−1) were injected into TA
muscles. A BTX 830 (BTX Harvard Apparatus) machine was set to 50 V, 5 pulses,
pulse length 60 ms, interval time 200 ms. Electrodes (tweezertrodes model 520)
were applied to muscle belly and then again in a perpendicularly manner. Mice
were allowed to fully recover overnight. All electroporated animals were standard
wild-type mice on the same background, no randomization was used in these
animal experiments, and staining analysis was performed in a blinded fashion.
A minimum of N= 3–5 mice (hind-limb leg electroporation of TA muscles) were
used for each individual electroporation experiment, which was sufficient to
provide adequate power for these experiments (0.80). In the event that protein
expression was not optimal within our detection limits (using biochemical or
histological methods) due to technical issues or limitations, samples were excluded
from our analysis.
Biochemical analysis of cells and muscle tissue. Biochemical analyses for
preparation of lysates were performed as follows: Cells from six-well culture dishes
or mouse TA muscles were sonicated and homogenized in RIPA buffer (50 mM
Tris pH 8.0, 150 mM NaCl, 1% NP-40, 5 mM EDTA, 0.5% sodium deoxycholate,
0.1% SDS) supplemented with 1 mM phenylmethylsulfonyl fluoride (PMSF), a
mixture of protease inhibitors (1 mgml−1 pepstatin, leuptin, N-p-tosyl-L-pheny-
lalanine chloromethyl ketone, Nα-Tosyl-L-lysine chloromethyl ketone hydro-
chloride, trypsin inhibitor; Sigma) and a mixture of phosphatase inhibitors (2 mM
imidazole, 1 mM NaF, 1 mM sodium orthovanadate; Sigma). Lysates were then
sonicated and centrifuged at 21,100×g for 30 min at 4 °C, and then rinsed in RIPA
buffer to deplete the soluble protein pool. The insoluble pelleted fractions were
then extracted in 75 μl (cells) or 250 μl (muscle tissues) urea buffer (7 M urea, 2 M
Thiourea, 4% CHAPS, 30 mM Tris, pH 8.5), sonicated, and centrifuged at 21,100×g
for 30 min at room temperature. All soluble and insoluble fractions were subse-
quently analyzed by western blotting using the following antibodies: rabbit
polyclonal anti-TDP-43 (Proteintech), rabbit polyclonal anti-phospho-TDP-43
(409/410) (Proteintech), rabbit polyclonal anti-GAPDH (Santa Cruz Biotechnol-
ogy), mouse mono, polyubiquitinylated conjugates (FK2, Enzo Life Sciences),
purified mouse anti-P62 (BD Transduction Laboratories), rabbit monoclonal anti-
COXIV (Cell Signaling), rabbit polyclonal anti-TOM20 (FL-145, Santa Cruz
Biotechnology), mouse anti-Cytochrome c (BD Pharmingen), rabbit polyclonal
anti-HA (Y-11, Santa Cruz Biotechnology), rabbit polyclonal anti-Hsp110
(Enzo Life Sciences), rat monoclonal anti-Hsp90 (16F1, Enzo Life Sciences), mouse
monoclonal anti-Hsp70/Hsp72 (C92F3A-5, Enzo Life Sciences), rabbit polyclonal
anti-Hsp40/Hdj1 (Enzo Life Sciences), goat polyclonal anti-Hsp27 (M-20, Santa
Cruz Biotechnology), rat monoclonal anti-HSF1 (10H8, Enzo Life Sciences).
Dilution ratios were 1:1000 for all the antibodies unless otherwise stated. Western
blot quantification was measured by densitometry and analyzed using ImageQuant
TL 1D v8.1 (GE Healthcare Life Sciences).
Immunocytochemistry and quantification. QBI-293 cells were grown on
PDL-coated coverslips and transfected as described above and cultured for the
indicated times. The cells were irreversibly fixed in 4% paraformaldehyde (PFA)
for 10 min, rinsed in PBS (three times) and permeabilized once with 0.2% Triton
X-100 (Sigma) in PBS for 10 min. Fixed cells were then blocked in 2% milk for 1 h
and incubated with specified primary antibodies overnight at 4 °C. Cells were
washed in PBS and incubated with Alexa-488 or 594-conjugated secondary anti-
body. Nuclei were counterstained with DAPI (Sigma). Cells were analyzed using a
LSM780 confocal laser microscope (Carl Zeiss). The relative inclusions counts were
normalized to that of cells co-transfected with control vector (PCDNA 3.1) or
DMSO mock treatment (in the case of HSF1A exposure), using >5 fields and a
minimum of 200 transfected cells. Sampling error was determined using the
SEM. Statistical analysis was performed with a two-tailed unpaired t-test with
unequal variance (significance set at p-value < 0.05). All of the quantitative
immunofluorescence analyses were independently validated and confirmed with at
least N= 3 biological replicates. Primary antibodies used for immunofluorescence
were as follows: rabbit polyclonal anti-GFP (FL, Santa Cruz Biotechnology), mouse
monoclonal anti-GFP (B2, Santa Cruz Biotechnology), rabbit polyclonal anti-
phospho-TDP-43 (409/410) (Proteintech), mouse mono, polyubiquitinylated
conjugates (FK2, Enzo Life Sciences), rabbit polyclonal anti-HA (Y-11, Santa
Cruz Biotechnology), rabbit polyclonal anti-proteasome 20 S core subunit (Enzo
Life Sciences), mouse monoclonal anti-SQSTM1(Abnova), mouse monoclonal
anti-UBQLN2 (555–624, Abnova), rabbit polyclonal anti-Hsp40/Hdj1 (Enzo Life
Sciences), goat polyclonal anti-Hsp27 (M-20, Santa Cruz Biotechnology). Antibody
dilutions were 1:500 for all antibodies unless otherwise noted.
Histological analysis of skeletal muscle. Electroporated TA muscles were
harvested and immediately immersed in 4% PFA overnight at 4 °C, and washed
with 1×PBS to remove traces of paraformaldehyde. The muscle tissues were then
transferred to 15% sucrose for OCT immersion embedding and sectioned into 10
μm serial sections. Double-labeling immunofluorescence (IF) was performed using
standard protocols. Briefly, sections were defrosted for 5 min, and fixed in 4% PFA
for 10 min. Sections were then washed with PBS three times for 5 min each, and
incubated in PBST (PBS and 0.1% Triton) for 15 min. The sections were further
blocked with PBTN (10% goat serum in PBST) for 1 h at room temperature in
humidified chamber, and subsequently incubated with primary antibodies of
interest overnight at 4 °C. Sections were washed and incubated with Alexa-488- or
594-conjugated secondary antibodies (Molecular Probes). Nuclei were counter-
stained with DAPI (Sigma). After washing in PBS, sections were coverslipped with
Fluoromount-G mounting medium (SouthernBiotech).
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CD8+ cytotoxic T-cell staining was performed by the Animal Histopathology
Core at the University of North Carolina. Sections were placed in acetone for 2 min
and then dried at room temp for 5–10 min. After 10 min PBS wash, the sections
were transferred to 10% formalin for 5 min and rinsed with PBS for 10 min. A
hydrogen peroxidase step was performed for 8 min and rinsed with PBS for 10 min.
The sections were then incubated with the primary CD8 antibody for 2 h at room
temperature and washed with PBS. Secondary anti-rat antibody (Omnimap) was
applied for 32 min at room temperature and rinsed. The sections were further
rhodamine stained for 16 min and rinsed. The sections were stained with Hoescht
33258 (Invitrogen solution) for 7 min and coverslipped using Prolong Gold
Antifade reagent (P36934, Life Technologies).
Images were obtained in a blinded manner (electroporated plasmids were
unknown at the time of imaging) using either an Olympus XI83 microscope or a
LSM780 confocal laser microscope (Carl Zeiss). The following primary antibodies
were used for IF analysis: rabbit polyclonal anti-GFP (FL, Santa Cruz
Biotechnology), mouse monoclonal anti-GFP (B2, Santa Cruz Biotechnology),
rabbit polyclonal anti-phospho(409/410)-TDP-43 (Proteintech), mouse mono,
polyubiquitinylated conjugates (FK2, Enzo Life Sciences), rabbit polyclonal anti-
HA (Y-11, Santa Cruz Biotechnology), rabbit polyclonal anti-proteasome 20S core
subunit (Enzo Life Sciences), mouse monoclonal anti-SQSTM1(Abnova), mouse
monoclonal anti-UBQLN2 (555–624, Abnova), rat monoclonal anti-HSF1(10H8,
Enzo Life Sciences), rabbit polyclonal anti-Hsp40/Hdj1 (Enzo Life Sciences), goat
polyclonal anti-Hsp27 (M-20, Santa Cruz Biotechnology), rat anti-mouse CD8
(eBioscience, 1:100). The average signal intensity of muscle sections was quantified
using Image J software. Three fields were examined, and sampling error was
calculated using the SEM. Statistical analysis was determined using a two-tailed
unpaired t-test with unequal variance (significance set at p-values <0.05). All
quantitative fluorescence was independently validated with a minimum of N= 3
biological replicates.
Immunohistochemical muscle staining was performed on paraffin-embedded
TA muscle tissues. Antigen retrieval was performed with a citrate based buffer
(Discovery CC2, 760–107, pH 6.0) for 64 min at 100 °C and then blocked with
hydrogen peroxidase for 12 min at room temperature. The slides were incubated
for 1 h at room temperature in a mixture of the primary antibody, a tris-based
diluent (Discovery PSS Diluent, 760–212), and the DAKO ARK’s Biotinylated and
Blocking Reagents (Dako ARK, Animal Research Kit), followed by Streptavidin-
HRP incubation (DAKO ARK) for 32 min at room temperature. The slides were
treated with 3,3′-diaminobenzidine (DAB) for visualization and Hematoxylin
counterstain for 12 min, and then Bluing Reagent for 4 min. The staining was
performed using Ventana’s Discovery Ultra Automated IHC staining system.
Primary antibodies used for IHC analysis were as follows: mouse monoclonal anti-
TDP-43 (human-specific TDP-43 antibody) (Proteintech, 1:250), rabbit polyclonal
anti-TDP-43 (total mouse and human TDP-43 antibody) (Proteintech, 1:500).
Images were obtained using an Olympus BX41 light microscope.
Injection of Evans blue dye. Mouse TA muscles were electroporated with TDP-
43-ΔNLS-K145Q plasmid for a total of 22 days. One day prior to muscle harvest,
the mice were i.p. injected with 1% EBD (Sigma) (w/v) in PBS(pH 7.5). After EBD
injection, animals were returned to their cage and allowed to recover overnight. TA
muscles were harvested after 24 h of EBD injection and analyzed by immunos-
taining using the indicated antibodies described in text.
Hematoxylin and eosin and Gomori trichrome staining. Mouse TA muscles
electroporated for the indicated times were harvested and immediately immersed
in 4% PFA overnight at 4 °C, washed with 1×PBS to remove traces of PFA and
paraffin-embedded. H&E staining was performed using standard protocol for
paraffin-embedded muscle tissue sections at 4 μm thickness. Briefly, unstained
slides were placed in an oven heated to 65–73 °C for 20–25 min to remove excess
paraffin. Paraffin was removed using xylene followed by ethanol dehydration.
The sections were rehydrated with tap water and stained with hematoxylin
(Richard-Allan Scientific) for 2 min. Richard Allan Scientific Clarifier 2 was applied
for 1 min. After three times water wash, Bluing Reagent (Richard-Allan Scientific)
was applied for 30 s and washed with water for 2.5 min. After 95% ethanol
dehydration, the eosin–phloxine stain (Richard-Allan Scientific) was applied for 1
min. The sections were then dehydrated in ethyl alcohol, cleared with xylene, and
coverslipped using a Leica Surgipath micromount medium (Leica Surgipath). For
Gomori trichrome staining, coverslips with sections were placed in a ceramic
staining rack (Thomas Scientific) and immersed in hematoxylin for 5 min. Sections
were immersed in Gomori trichrome for 10 min and differentiated using 0.2%
acetic acid. The sections were then dehydrated in ethyl alcohol, cleared with xylene,
and coverslipped using a Leica Surgipath micromount medium. Images were
obtained using an Olympus BX41 light microscope.
Histological analysis of ALS spinal cord. ALS spinal cord sections were kindly
provided by Dr John Q. Trojanowski (University of Pennsylvania) from two
patients harboring abundant acetylated TDP-43 pathology27.
Hsp40 immunohistochemical analysis and dual-color IF staining of Hsp40
(rabbit polyclonal anti-Hsp40/Hdj 1, Enzo Life Sciences, 1:150) and phospho-TDP-
43 was performed by the UNC Translational Pathology Laboratory. Slides were
dewaxed in Bond Dewax solution (Leica Biosystems) and hydrated in Bond Wash
solution (Leica Biosystems). Antigen retrieval for both stains were done for 30 min
in Bond-epitope retrieval solution 1 (pH 6.0, Leica Biosystems), followed with 5
min endogenous peroxidase blocking with Bond peroxide blocking solution
(Leica Biosystems). The protein blocking reagent (Leica Biosystems) was added for
10 min. Primary antibodies were applied for 1 h. Chromogenic detection of Hsp40
was done using Bond Polymer Refine Detection system with DAB visualization and
Hematoxylin counterstain. Stained slides were dehydrated and coverslipped. For
dual-color IF staining, first phospho-TDP-43 was detected with rabbit anti-rat IgG
(Vector labs), Bond polymer (Leica Biosystems) and Tyramide -Cy5 (Perkin
Elmer), then with Hsp40 with Bond polymer and Tyramide Cy3 (Perkin Elmer).
After completion of the first stain and before addition of the second primary
antibody the appropriate antigen retrieval protocol and peroxide blocking
steps as described above were applied. Slides were counterstained with
Hoechst (Invitrogen) and mounted with ProLong Gold antifade reagent
(Life Technologies). IHC stained slides were digitally imaged in Aperio
ScanScope XT (Leica Biosystems) using ×20 objective. High-resolution acquisition
of double-color IF slides in the DAPI, Cy3, and Cy5 channels was performed in
Aperio ScanScope FL (Leica Biosystems) using ×20 objective.
Immunoprecipitation and mass spectrometry analysis. Immunoprecipitation
followed by mass spectrometry was performed as follows. For cell-based mass
spectrometry analysis, 10 cm dishes of QBI-293 cells were transiently transfected
with TDP-43-ΔNLS (acetylation mapping) or TDP-43-ΔNLS-K145Q (ubiquiti-
nation mapping) plasmids. Cell lysates were generated and total TDP-43 was
immunoprecipitated using anti-TDP-43 antibody (clone 171), which was
complexed to protein A/G beads (Sigma). The immunoprecipitated TDP-43 was
analyzed either directly without SDS-PAGE, or alternatively analyzed by SDS-
PAGE electrophoresis and Coomassie staining, and finally gel excised for analysis
by nanoLC/nanospray/MS/MS. Acetylated lysine mapping was performed at
the University of Pennsylvania proteomics core facility using Xcalibur 2.0
(ThermoFisher), PEAKS 6.0 (Bioinformatics Solutions Inc.), and Scaffold 3
(Proteome Software) software packages. The significance cutoffs used were as
follows: peptide p-value < 95%; protein p-value < 99.0%. TDP-43 ubiquitination
site mapping was performed with both discovery and target proteomics using a
quadrupole orbitrap mass spectrometer operating in a traditional data-dependent
top 12 mode and in parallel reaction monitoring mode (PRM), respectively. PRM
data were analyzed in Skyline.
Data availability. All relevant data are available from the corresponding author
upon reasonable request.
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